1. Home
  2. EXFY vs MDXH Comparison

EXFY vs MDXH Comparison

Compare EXFY & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Expensify Inc.

EXFY

Expensify Inc.

HOLD

Current Price

$1.02

Market Cap

132.1M

Sector

Technology

ML Signal

HOLD

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$2.03

Market Cap

149.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXFY
MDXH
Founded
2008
2003
Country
United States
Belgium
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
132.1M
149.0M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
EXFY
MDXH
Price
$1.02
$2.03
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$4.50
$7.67
AVG Volume (30 Days)
559.8K
186.3K
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$142,101,000.00
N/A
Revenue This Year
$0.42
$30.78
Revenue Next Year
$0.11
$18.31
P/E Ratio
N/A
N/A
Revenue Growth
2.06
N/A
52 Week Low
$0.69
$1.67
52 Week High
$3.06
$5.33

Technical Indicators

Market Signals
Indicator
EXFY
MDXH
Relative Strength Index (RSI) 62.69 35.43
Support Level $0.78 $1.96
Resistance Level $1.54 $2.37
Average True Range (ATR) 0.06 0.13
MACD 0.03 0.02
Stochastic Oscillator 89.59 23.81

Price Performance

Historical Comparison
EXFY
MDXH

About EXFY Expensify Inc.

Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: